Stock Events

Stock Events

GH Research 

$20.49
65
-$0.63-2.98% Today

Statistics

Day High
21.95
Day Low
20.43
52W High
25.94
52W Low
11.32
Volume
3,870,759
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.37
-0.29
-0.22
-0.15
Expected EPS
-0.32
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-42.92MNet Income

Analyst Ratings

41.67Average Price Target
The highest estimate is 65.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GHRS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.63B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with GH Research's focus on mental health treatments.
AtaiBeckley
ATAI
Mkt Cap1.44B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health disorders, competing in the same space as GH Research.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including mental health treatments, positioning it as a competitor to GH Research.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics explores the use of psychedelics in treatments, including mental health, which competes with GH Research's therapeutic focus.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, has developed a ketamine-based treatment for depression, competing in the mental health treatment space with GH Research.

About

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Show more...
CEO
Mr. Florian Schonharting M.Sc. (Econ)
Employees
50
Country
Ireland
ISIN
IE000GID8VI0

Listings

STU
DE
1KA.STU
F
DE
1KA.F
MU
DE
1KA.MU
XNAS
US
GHRS

0 Comments

Share your thoughts

FAQ

What is GH Research stock price today?▼
The current price of GHRS is $20.49 USD — it has decreased by -2.98% in the past 24 hours. Watch GH Research stock price performance more closely on the chart.
What is GH Research stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange GH Research stocks are traded under the ticker GHRS.
Is GH Research stock price growing?▼
GHRS stock has risen by +2.49% compared to the previous week, the month change is a -3.6% fall, over the last year GH Research has showed a +61.6% increase.
When is the next GH Research earnings date?▼
GH Research is going to release the next earnings report on August 26, 2026.
What were GH Research earnings last quarter?▼
GHRS earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.29 USD resulting in a -5.68% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is GH Research revenue for the last year?▼
GH Research revenue for the last year amounts to 0 USD.
What is GH Research net income for the last year?▼
GHRS net income for the last year is -42.92M USD.
How many employees does GH Research have?▼
As of June 15, 2026, the company has 50 employees.
In which sector is GH Research located?▼
GH Research operates in the Health & Wellness sector.
When did GH Research complete a stock split?▼
GH Research has not had any recent stock splits.
Where is GH Research headquartered?▼
GH Research is headquartered in Dublin, Ireland.